Asston Pharmaceuticals approved raising ₹27.72 crore by issuing 24.10 lakh equity shares at ₹115 each. The funds will bolster company capital, but existing shareholders face equity dilution.
Asston Pharmaceuticals to Raise ₹27.72 Crore via Preferential Issue
Asston Pharmaceuticals Limited announced its board has approved a plan to raise ₹27.72 crore through a preferential issue of 24,10,431 equity shares.
Reader Takeaway: Capital infusion for growth, but potential equity dilution for existing shareholders.
What just happened
The company's Board of Directors, in a meeting on July 02, 2026, approved the preferential issue. This involves allotting 24,10,431 equity shares at a price of ₹115 per share (including a premium of ₹105) to non-promoter investors.
Why this matters
This capital infusion of ₹27.72 crore is expected to strengthen the company's financial resources. However, the issuance of new shares will lead to a dilution of existing equity holdings for current shareholders.
The backstory
Asston Pharmaceuticals is seeking to enhance its capital base to fund its operations and potential growth initiatives. The company is now seeking shareholder approval for this strategic move.
What changes now
The proposal will be put forth for shareholder approval at an Extraordinary General Meeting (EGM) scheduled for July 31, 2026. If approved, the company's shareholding structure will change, with new investors like Vijay Rathee and Vijaylaxmi Infra Projects Private Limited gaining significant stakes.
Risks to watch
Existing shareholders need to evaluate the impact of equity dilution and assess if the capital raised will be effectively utilized to generate adequate returns.
Peer comparison
Information regarding peer company capital raises through preferential issues is not directly available in the filing.
Context metrics (time-bound)
- Capital Raise Target: ₹27.72 crore
- Shares to be Issued: 24,10,431
- Issue Price: ₹115 per share
- Board Approval Date: July 02, 2026
- EGM Date: July 31, 2026
What to track next
Investors should closely follow the outcome of the EGM on July 31, 2026, and monitor the company's disclosures regarding the utilization of the raised funds.